Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95561 | 0.87 | MAPT (1.00) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL7164868 | 0.82 | MAPT (0.84) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL10353552 | 0.80 | MAPT (0.76) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL95687 | 0.79 | MAPT (0.74) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL10353546 | 0.78 | MAPT (0.72) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL10353602 | 0.78 | MAPT (0.72) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL102602 | 0.78 | MAPT (0.77) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL13783550 | 0.76 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL10360050 | 0.76 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL9138464 | 0.76 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | POLRMT, EIF2AK2, DUT | MAPT 4232/4885L3MBTL1 2089/4885MAPK1 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.